Prognostic factors for survival of patients with advanced urothelial tumors treated with methotrexate, vinblastine, doxorubicin, and cisplatin chemotherapy Journal Article


Authors: Geller, N. L.; Sternberg, C. N.; Penenberg, D.; Scher, H.; Yagoda, A.
Article Title: Prognostic factors for survival of patients with advanced urothelial tumors treated with methotrexate, vinblastine, doxorubicin, and cisplatin chemotherapy
Abstract: Between February 1983 and February 1986, 132 patients with advanced urothelial tract tumors were treated with methotrexate, vinblastine, Adriamycin (doxorubicin), and cisplatin (M‐VAC) chemotherapy. Analysis of prognostic factors for survival of the first 92 patients was undertaken using the Cox proportional hazards model. Normal alkaline phosphatase and high Karnofsky performance status (KPS) were predominant for long survival. Patients 60 years or older at initiation of therapy were likely to survive longer than younger patients, perhaps indicating physician selectivity of older patients for this therapy, and those with initial hemoglobin in the normal range were also likely to survive longer. The additional 40 patients' data were used to validate the model. Clinical implications of the prognostic factors are discussed. Copyright © 1991 American Cancer Society
Keywords: survival; adult; aged; bone neoplasms; survival rate; major clinical study; cisplatin; doxorubicin; liver neoplasms; conference paper; methotrexate; antineoplastic combined chemotherapy protocols; age factors; vinblastine; risk; alkaline phosphatase; bilirubin; urothelium; bladder neoplasms; hemoglobins; intravenous drug administration; middle age; cancer; prognosis; human; male; female; priority journal; support, u.s. gov't, p.h.s.
Journal Title: Cancer
Volume: 67
Issue: 6
ISSN: 0008-543X
Publisher: Wiley Blackwell  
Date Published: 1991-03-15
Start Page: 1525
End Page: 1531
Language: English
DOI: 10.1002/1097-0142(19910315)67:6<1525::Aid-cncr2820670611>3.0.Co;2-8
PUBMED: 2001540
PROVIDER: scopus
DOI/URL:
Notes: Article -- Export Date: 27 September 2019 -- Source: Scopus
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Howard Scher
    1130 Scher
  2. Nancy L. Geller
    65 Geller
  3. Alan Yagoda
    51 Yagoda